Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$227.76 USD
-1.08 (-0.47%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $227.64 -0.12 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
BDX 227.76 -1.08(-0.47%)
Will BDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BDX
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?
BDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
Earnings Season Update and Analyst Reports for Broadcom, JNJ & Verizon
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
Other News for BDX
BD to Announce Financial Results for its Third Quarter of Fiscal 2024
GSH Unveils New Upscale Hotel in Chongqing
ICU Medical - Stabilization Is In Sight, But The Road Back Is Difficult
New BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases
Dividend Champion, Contender, And Challenger Highlights: Week Of June 23